About
Inflammatix is a biotechnology company at the intersection of molecular biology, bioinformatics, and artificial intelligence. Their core platform 'reads' the immune system by measuring mRNA signatures of immune cells circulating in the blood, enabling detection of infections that pathogen-targeting tests often miss due to local containment. Their flagship product, TriVerity, is designed for emergency department use and provides three simultaneous actionable scores: the likelihood of a bacterial infection, the likelihood of a viral infection, and the probability of severe illness progression—defined as the risk of requiring mechanical ventilation, vasopressors, or renal replacement therapy within seven days. Powered by machine learning classifiers and clinically validated genomic biomarkers, TriVerity has been shown to outperform the current standard of care in both accuracy and speed. The technology addresses a critical gap in acute care: rapid, confident differentiation between infection types and severity levels when time, space, and diagnostic certainty are at a premium. Inflammatix's approach leverages millions of years of immune system evolution, translating complex biological signals into clear, clinically actionable guidance. TriVerity received FDA clearance, making it the first test of its kind to reach the market. The platform is built on deep expertise in bioinformatics, AI, and molecular diagnostics, positioning Inflammatix as a pioneer in host-response diagnostics for sepsis and acute infection management.
Key Features
- Host Immune Response Analysis: Measures mRNA signatures from circulating immune cells in whole blood to detect infections that pathogen-targeting tests miss.
- Three Actionable Diagnostic Scores: TriVerity simultaneously provides likelihood scores for bacterial infection, viral infection, and all-cause illness severity.
- Machine Learning Classifiers: Powered by advanced bioinformatics and AI models trained on large clinical datasets to deliver superior diagnostic accuracy.
- FDA-Cleared Point-of-Care Testing: TriVerity is the first-in-class FDA-cleared rapid diagnostic designed for emergency department use.
- Prognostic Clarity: Predicts risk of progression to mechanical ventilation, vasopressors, or renal replacement therapy within seven days.
Use Cases
- Emergency department triage to rapidly differentiate bacterial from viral infections and guide antibiotic stewardship.
- Early sepsis identification and severity stratification to prioritize ICU-level interventions.
- Prognostic assessment of illness progression risk to allocate hospital resources more effectively.
- Reducing unnecessary antibiotic prescriptions by accurately ruling out bacterial infections at the point of care.
- Supporting time-sensitive clinical decisions when standard diagnostic workups are too slow for critically ill patients.
Pros
- FDA Cleared: TriVerity has received FDA clearance as a first-in-class diagnostic, establishing regulatory credibility and clinical trust.
- Outperforms Standard of Care: Clinically proven to deliver better diagnostic accuracy than current standard-of-care approaches for acute infections and sepsis.
- Comprehensive Simultaneous Output: Provides three scores in one test, reducing the need for multiple diagnostic workups and accelerating clinical decision-making.
- Catches Locally Contained Infections: Unlike pathogen-targeting tests, Inflammatix's host-response approach detects infections that don't penetrate the bloodstream.
Cons
- Highly Specialized Use Case: Designed exclusively for acute infection and sepsis diagnosis in clinical settings, with no general-purpose utility outside healthcare.
- Requires Clinical Infrastructure: TriVerity is a point-of-care medical device requiring trained clinical staff and a hospital or emergency department environment.
- Limited Public Pricing Transparency: As a commercial medical device, pricing and procurement details are not publicly disclosed and require direct engagement with Inflammatix.
Frequently Asked Questions
What is TriVerity?
TriVerity is Inflammatix's FDA-cleared rapid point-of-care diagnostic test that uses mRNA profiling and machine learning to deliver three simultaneous scores: likelihood of bacterial infection, viral infection, and all-cause illness severity.
How does Inflammatix read the immune response?
Inflammatix measures mRNA expression profiles from immune cells circulating in whole blood. These cells fight infections locally and then enter the bloodstream carrying detectable 'signatures' that reveal the type and severity of infection.
Who is TriVerity designed for?
TriVerity is designed for emergency department clinicians who need rapid, accurate diagnostic guidance when evaluating patients with suspected acute infections or sepsis.
Is TriVerity FDA approved?
Yes. Inflammatix received FDA clearance for the TriVerity test, making it the first-in-class rapid host-response diagnostic to achieve regulatory authorization in the United States.
Why is a host-response test better than pathogen-targeting tests for sepsis?
Most infections are locally contained and do not enter the bloodstream, making pathogen-targeting tests insensitive. Host-response tests like TriVerity detect immune cell activity in the blood regardless of where the infection is, yielding higher sensitivity and accuracy.
